Literature DB >> 9918244

Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity.

S Zucker1, N Mian, M Drews, C Conner, A Davidson, F Miller, P Birembaut, B Nawrocki, A J Docherty, R A Greenwald, R Grimson, P Barland.   

Abstract

OBJECTIVE: In view of evidence that stromelysin-1 and collagenase-1 are involved in tissue injury in inflammatory joint diseases, we sought to determine whether matrix metalloproteinases (MMP) are implicated in the pathophysiology of systemic lupus erythematosus (SLE).
METHODS: Seventy-three patients with SLE and 39 healthy subjects were evaluated. Serum levels of MMP and tissue inhibitor of metalloproteinases were measured.
RESULTS: Serum stromelysin-1 levels were significantly increased in patients with SLE (416+/-252 ng/ml) compared to healthy subjects (125+/-93 ng/ml). No correlation between serial measurements of stromelysin-1 and disease activity in SLE patients was noted. Serum collagenase-1, gelatinase A, and TIMP-1 levels were not increased in SLE.
CONCLUSION: Serum concentrations of stromelysin-1 are increased in SLE, but the levels do not correlate with disease activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9918244

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.

Authors:  C Ribbens; M Martin y Porras; N Franchimont; M-J Kaiser; J-M Jaspar; P Damas; F A Houssiau; M G Malaise
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

2.  Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus.

Authors:  A Faber-Elmann; Z Sthoeger; A Tcherniack; M Dayan; E Mozes
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

3.  Concentrations of circulating matrix metalloproteinase 9 inversely correlate with autoimmune antibodies to double stranded DNA: implications for monitoring disease activity in systemic lupus erythematosus.

Authors:  G S Makowski; M L Ramsby
Journal:  Mol Pathol       Date:  2003-08

4.  Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus.

Authors:  Ewa Robak; Agnieszka Wierzbowska; Magdalena Chmiela; Liliana Kulczycka; Anna Sysa-Jedrejowska; Tadeusz Robak
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

Review 5.  Human and Murine Evidence for Mechanisms Driving Autoimmune Photosensitivity.

Authors:  Sonya J Wolf; Shannon N Estadt; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  Front Immunol       Date:  2018-10-23       Impact factor: 7.561

6.  Association between Serum Matrix Metalloproteinase- (MMP-) 3 Levels and Systemic Lupus Erythematosus: A Meta-analysis.

Authors:  Jiwon M Lee; Andreas Kronbichler; Se Jin Park; Seong Heon Kim; Kyoung Hee Han; Hee Gyung Kang; Il Soo Ha; Hae Il Cheong; Ki Hwan Kim; Gaeun Kim; Dong Soo Kim; Hyun Wook Chae; Chul Ho Lee; Keum Hwa Lee; Jae Il Shin
Journal:  Dis Markers       Date:  2019-07-18       Impact factor: 3.434

Review 7.  Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis.

Authors:  Anders Tveita; Ole Petter Rekvig; Svetlana N Zykova
Journal:  Arthritis Res Ther       Date:  2008-12-01       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.